Novavax to Participate in BofA Securities 2022 Healthcare Conference
Novavax, a biotechnology company based in Gaithersburg, Maryland, will participate in the BofA Securities 2022 Healthcare Conference on May 11, 2022. The company's COVID-19 vaccine candidate, NVX-CoV2373, will be discussed during the fireside chat scheduled from 5:20 - 5:50 p.m. PDT. Executives Gregory M. Glenn and John J. Trizzino will represent Novavax. A replay of the session will be available on the company’s website for 90 days following the event. Novavax continues to develop innovative vaccines for serious infectious diseases and has received conditional authorization for NVX-CoV2373 globally.
- None.
- None.
GAITHERSBURG, Md., May 4, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in BofA Securities 2022 Healthcare Conference. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.
Conference Details: | ||||||
Fireside Chat | ||||||
Date: | Wednesday, May 11, 2022 | |||||
Time: | 5:20 – 5:50 p.m. Pacific Daylight Time (PDT) | |||||
Location: | Encore Hotel in Las Vegas, Nevada | |||||
Moderator: | Alec Stranahan | |||||
Novavax participants: | Gregory M. Glenn, M.D., President, Research and Development and John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer | |||||
Conference | ||||||
Event: | Investor Meetings | |||||
Date: | Wednesday, May 11, 2022 | |||||
A replay of the recorded fireside session will be available through the events page of the Company's website at ir.novavax.com for 90 days.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, has received conditional authorization from multiple regulatory authorities globally, including the European Commission and the World Health Organization. The vaccine is also under review by multiple regulatory agencies worldwide. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and NanoFlu*, its quadrivalent influenza investigational vaccine candidate. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter, LinkedIn, Instagram and Facebook.
*NanoFlu identifies a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by Novavax. This investigational candidate was evaluated during a controlled phase 3 trial conducted during the 2019-2020 influenza season.
Contacts:
Investors
Novavax, Inc.
Alex Delacroix | 240-268-2022
ir@novavax.com
Media
Ali Chartan | 240-720-7804
media@novavax.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-bofa-securities-2022-healthcare-conference-301539882.html
SOURCE Novavax, Inc.
FAQ
When is Novavax participating in the BofA Securities 2022 Healthcare Conference?
What time will Novavax's fireside chat begin at the BofA conference?
Who are the representatives from Novavax at the BofA conference?
What is the primary topic of discussion during Novavax's session at the conference?
How can I access the replay of Novavax's fireside chat?
Has NVX-CoV2373 received any regulatory approvals?
